Chris Ryan

Encorafenib plus cetuximab and mFOLFOX6 improved progression-free survival in BRAF V600E–mutated metastatic colorectal cancer.

The addition of ORIC-944 to an AR pathway inhibitor generated PSA responses in metastatic castration-resistant prostate cancer.

The FDA granted priority review to sevabertinib for pretreated, advanced non–small cell lung cancer harboring HER2 mutations.

Findings from a matching-adjusted indirect comparison showed a PFS benefit with zanubrutinib vs orelabrutinib in relapsed/refractory mantle cell lymphoma.

Talquetamab plus teclistamab produced responses with a high rate of infections in relapsed/refractory multiple myeloma.

Momelotinib was associated with anemia benefits and reduced transfusion burden in myelofibrosis in a post hoc analysis of 4 trials.

The EMA’s CHMP has recommended the approval of inavolisib plus palbociclib/fulvestrant in PIK3CA-mutated, ER-positive advanced breast cancer.

Two-year follow-up data continued to show an overall survival benefit with glofitamab plus chemotherapy in relapsed/refractory DLBCL.

The FDA granted breakthrough device designation to EnVisio X1 for minimally invasive surgery in cancer care.

The FDA’s ODAC voted against the risk/benefit profile of UGN-102 for recurrent, low-grade, intermediate-risk non–muscle-invasive bladder cancer.

The FDA’s ODAC voted against the applicability of STARGLO trial results to U.S. patients with relapsed/refractory DLBCL.

An exploratory ctDNA analysis from postMONARCH highlighted the benefit of abemaciclib plus fulvestrant across HR-positive breast cancer subgroups.

Two belantamab mafodotin–based combinations have been approved in Japan for relapsed/refractory multiple myeloma.

Oncology experts detail their most highly-anticipated hematology abstracts and data to watch at the upcoming 2025 ASCO Annual Meeting.

Durvalumab plus tremelimumab and trastuzumab produced responses in trastuzumab-resistant, HER2-positive advanced breast cancer.

An analysis from PADA-1 showed the emergence of ESR1 mutations was uneven over time in hormone receptor–positive, HER2-negative metastatic breast cancer.

First-line eftilagimod alpha plus pembrolizumab and chemotherapy produced responses in advanced nonsquamous non–small cell lung cancer.

The FDA has approved the VENTANA MET (SP44) RxDx Assay as a companion diagnostic for telisotuzumab vedotin in non–small cell lung cancer.

The FDA approved telisotuzumab vedotin for pretreated advanced NSCLC harboring high c-MET protein overexpression.

The FDA has approved belzutifan for advanced, unresectable, or metastatic pheochromocytoma and paraganglioma.

Generic formulations of eltrombopag are now available for severe aplastic anemia and immune thrombocytopenia.

Switzerland has approved piflufolastat (18F) as an imaging agent to detect PSMA-positive lesions in prostate cancer.

The allogeneic CAR T-cell therapy CT0596 was safe with clinical activity in relapsed/refractory multiple myeloma.

The FDA granted fast track designation to ADRX-0706 for locally advanced or metastatic squamous cell cervical cancer.

The Signatera MRD assay was associated with high levels of sensitivity and specificity in sarcomas.

The addition of VCN-01 to gemcitabine and nab-paclitaxel improved survival in newly diagnosed metastatic pancreatic cancer.

The addition of elraglusib to gemcitabine and nab-paclitaxel improved overall survival is first-line metastatic pancreatic cancer.

The European Commission has approved acalabrutinib plus bendamustine and rituximab for previously untreated, transplant-ineligible mantle cell lymphoma.

No recurrences, disease-free survival events, or deaths were reported in select patients with breast cancer who had surgery omitted.

The FDA issued a complete response letter to the new drug application seeking the approval of TLX101-CDx as an imaging agent for glioma.